Skip to main content
Clinical Trials/NCT04999241
NCT04999241
Not yet recruiting
Phase 4

The Role of Combined Application of Exclusive Enteral Nutrition in the Induction of Remission for Children With Newly Diagnosed Moderate to Severe Ulcerative Colitis

Children's Hospital of Fudan University0 sites40 target enrollmentMarch 1, 2025

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Exclusive Enteral Nutrition
Sponsor
Children's Hospital of Fudan University
Enrollment
40
Primary Endpoint
The mucosal healing rate
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

The role of exclusive enteral nutrition (EEN) in the induction of remission in pediatric patients with Crohn's disease had been well documented. But the role of EEN in children with Ulcerative Colitis (UC) was not clear. In this study, EEN will be combined with corticosteroids or infliximab in the induction of remission in pediatric UC patients with moderate to severe disease activity. The mucosal healing rate at week12 will be compared between the two groups (combine with EEN group VS non-combine group).

Detailed Description

The role of exclusive enteral nutrition (EEN) in the induction of remission in pediatric patients with Crohn's disease(CD) had been well documented. Several randomized controlled trial studies found that the overall induction of remission was equipotent with EEN compared to corticosteroids for pediatric CD. However, in promoting mucosal healing and improving the nutritional status, EEN was much better than corticosteroids. But the role of EEN in children with Ulcerative Colitis (UC) was not clear. In this study, EEN will be combined with corticosteroids or infliximab in the induction of remission in pediatric UC patients with moderate to severe disease activity. The mucosal healing rate at week 12 will be compared between the two groups (combine with EEN group VS non-combine group).The sustained corticosteroid-free clinical remission rate and treatment modification rate during the first year will also be evaluated.

Registry
clinicaltrials.gov
Start Date
March 1, 2025
End Date
December 31, 2027
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ying HUANG

Chief of Gastroenterology

Children's Hospital of Fudan University

Eligibility Criteria

Inclusion Criteria

  • Newly diagnosed UC
  • Years 6 to 18
  • Moderate to severe disease activity at diagnosis

Exclusion Criteria

  • With mild disease activity at diagnosis
  • Had been treated with corticosteroids or biologics

Outcomes

Primary Outcomes

The mucosal healing rate

Time Frame: 12 week after intervention

The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) ≦1 points is defined as mucosal healing. This will be evaluated by inflammatory bowel disease endoscopist.

Secondary Outcomes

  • sustained corticosteroid-free clinical remission rate(1 year after intervention)
  • Treatment modification rate(1 year after intervention)

Similar Trials